MedPath

Tyligand Bioscience (Shanghai) Limited

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:1
Completed:0

Trial Phases

1 Phases

Phase 1:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (100.0%)

TSN084 Treating Patients With Advanced Malignant Tumors

Phase 1
Recruiting
Conditions
Malignant Neoplasm
Interventions
First Posted Date
2024-04-26
Last Posted Date
2024-07-29
Lead Sponsor
Tyligand Bioscience (Shanghai) Limited
Target Recruit Count
114
Registration Number
NCT06386705
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Peking university cancer hospital, Beijing, Beijing, China

A Study of TSN1611 Treating Patients with Advanced Solid Tumors Harboring KRAS G12D Mutation

Phase 1
Recruiting
Conditions
Malignant Neoplasm
Interventions
First Posted Date
2024-04-26
Last Posted Date
2025-03-24
Lead Sponsor
Tyligand Pharmaceuticals (Suzhou) Limited
Target Recruit Count
150
Registration Number
NCT06385925
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

NEXT Oncology, San Antonio, Texas, United States

🇺🇸

NEXT Virginia, Fairfax, Virginia, United States

and more 3 locations

TSN222 in Subjects With Advanced Solid Tumors or Lymphomas

Phase 1
Recruiting
Conditions
Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma
Interventions
Drug: Phase II-Advanced melanoma
Drug: Phase I dose escalation
Drug: Phase II-HNSCC
Drug: Phase II-solid tumors or lymphomas
First Posted Date
2023-05-06
Last Posted Date
2024-07-29
Lead Sponsor
Tyligand Bioscience (Shanghai) Limited
Target Recruit Count
162
Registration Number
NCT05842785
Locations
🇨🇳

Fudan Cancer Hospital, Shanghai, Shanghai, China

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.

Phase 1
Active, not recruiting
Conditions
Cancer (With or Without Metastasis)
Interventions
First Posted Date
2022-03-29
Last Posted Date
2024-06-25
Lead Sponsor
Tyligand Bioscience (Shanghai) Limited
Target Recruit Count
74
Registration Number
NCT05300438
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.